FREESTYLE LIBRE TO BE AVAILABLE FOR ALL T1s
NICE has updated the guidance for CGM use in England and all type 1s will get access. No other criteria! Freestyle Libre or other CGM for all regardless of postcode and in preference to finger prick testing etc.
Offer adults with type 1 diabetes a choice of real-time continuous glucose monitoring (rtCGM) or intermittently scanned continuous glucose monitoring (isCGM, commonly referred to as 'flash'), based on their individual preferences, needs, characteristics, and the functionality of the devices available. See box 1 for examples of factors to consider as part of this discussion.
Read more in our blog here.
See official guidance NG17 here.
DEXCOM ANNOUNCE ONE CGM TO LAUNCH IN UK IN MAY
1st April 2022
Dexcom One is a simplified version of the Dexcom G6 system and is currently available in Bulgaria, Latvia, Estonia and Lithuania.
Dexcom One will not offer all the same functionality as the standard G6 but offers many of the benefits for a reduced cost. There will also be a version of the next-generation G7 available as a Dexcom One system.
At the ATTD Conference in Barcelona on 28 April, Dexcom released this chart showing the differing options with Dexcom CGMs:
Find out more about the Dexcom ONE in our review here.
SENSEONICS ANNOUNCES FIRST IMPLANT OF 6 MONTH SENSOR
6th April 2022
In February 2022, Senseonics were given approval by the American FDA for their E3 Eversense, an implantable sensor that lasts 6 months. Now they have reported that the first one has been implanted in a person with type one diabetes.
It is the longest lasting CGM available, with a 6-month sensor wear duration, with essentially two sensor insertion and removal procedures per year and it gives wearers discrete on-body vibratory alerts through a removable transmitter.
The MARD is only 8.5% giving it a high level of accuracy compared to other CGMs - the Dexcom G6 is 9.0% and Freestyle Libre 2 has a MARD of 9.2%.
Read more here.
REAL_TIME CGM NOW ON NHS PRESCRIPTION
The GlucoRx Aidex CGM is now available in England on prescription. It gives updates directly to an app every 5 minutes without scanning!
Read our review of this medtech here: GlucoRx Aidex review.
LIBRE 1 TO BE WITHDRAWN IN AUSTRALIA
21st April 2022
Libre 1 is to be withdrawn in Australia with only 5 weeks notice.
In an announcement today Abbott Diabetes Care have advised that they will soon be replacing FreeStyle Libre with FreeStyle Libre 2 sensors in Australia.
From 30 May 2022 users will be automatically updated to FreeStyle Libre 2.
Read more here.
ABBOTT's FINANCIAL RESULTS UPDATE
Abbott have announced their financial results for the first quarter ended March 31, 2022. There was strong growth in diabetes care with sales of FreeStyle Libre bringing revenue of approximately $1.0 billion in the quarter, representing sales growth of 20.4% on a reported basis and 26.2% on an organic basis.
Other highlights from the reports are:
- In February, Abbott received FDA approval for an expanded indication for its CardioMEMS™ HF system, a small implantable sensor and remote monitoring system that can detect early warning signs of worsening heart failure.
- In March, Abbott announced its FreeStyle Libre® system is the first and only continuous glucose monitoring (CGM) system to gain expanded reimbursement in Japan to now include all people with diabetes who use insulin.
Read more here.
YPSOMED, FREESTYLE LIBRE 3 & CAMDIAB ANNOUNCE PARTNERSHIP TO OFFER NEW AID SYSTEM
27th April 2022
The initial focus of the partnership will be in European countries.
Read more here:
PREVIOUS MONTHS' NEWS
Read March News: Click here.
Read February News: Click here.
Read January News: Click here.